Pfizer (NYSE:PFE) significantly expanded its metabolic footprint on Friday, announcing that Chinese regulators have approved its GLP-1 receptor agonist, Xianweiying (ecnoglutide), for long-term weight management in overweight and obese adults.
The approval by the National Medical Products Administration (NMPA) makes Xianweiying the first "cAMP-biased" GLP-1 treatment approved globally for obesity, a unique mechanism designed to enhance weight loss while potentially reducing gastrointestinal side effects.
The move follows a strategic licensing deal finalized in February 2026, in which Pfizer paid Sciwind Biosciences up to $495 million for exclusive commercialization rights in mainland China.
While Sciwind remains the manufacturer and developer, Pfizer will leverage its vast Chinese sales infrastructure to challenge incumbents.
The market is currently dominated by Novo Nordisk's Wegovy and Innovent Biologics' Xinermei, the latter of which outperformed Wegovy on major Chinese e-commerce platforms in 2025 with $61 million in sales compared to Wegovy's $38 million.